ULTRAGENYX PHARMACEUTICAL INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $1.31 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-05-08
- ULTRAGENYX PHARMACEUTICAL INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $1.31M.
- ULTRAGENYX PHARMACEUTICAL INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $2.41M, a 48180.00% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $198.00K, a 78.38% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2016-12-31 was $5.00K.
- ULTRAGENYX PHARMACEUTICAL INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $476.00K, a 257.89% increase from fiscal 2016.
- ULTRAGENYX PHARMACEUTICAL INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $133.00K.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $1.31M 10-Q · filed 2018-05-08 | $3.73M derived: sum of 2 quarters · filed 2018-05-08 | $3.93M derived: sum of 3 quarters · filed 2018-05-08 | |
| 2017-12-31 | $2.41M 10-K · filed 2018-02-21 | $2.61M derived: sum of 2 quarters · filed 2018-02-21 | $476.00K 10-K · filed 2018-02-21 | |
| 2017-09-30 | $198.00K 10-K · filed 2018-02-21 | $198.00K 10-Q · filed 2017-11-03 | ||
| 2016-12-31 | $5.00K 10-K · filed 2018-02-21 | $116.00K derived: sum of 2 quarters · filed 2018-02-21 | $133.00K derived: sum of 3 quarters · filed 2018-02-21 | $133.00K 10-K · filed 2018-02-21 |
| 2016-09-30 | $111.00K 10-K · filed 2018-02-21 | $128.00K derived: sum of 2 quarters · filed 2018-02-21 | $128.00K 10-Q · filed 2017-11-03 | |
| 2016-06-30 | $17.00K 10-K · filed 2018-02-21 | $17.00K 10-Q · filed 2017-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |